Holen Sie sich die Stockscreener-App
10.04
10.57%
0.96
Handel nachbörslich:
10.04
Schlusskurs vom Vortag:
$9.08
Offen:
$9.05
24-Stunden-Volumen:
1.13M
Relative Volume:
1.02
Marktkapitalisierung:
$527.30M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.6802
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
-0.69%
1M Leistung:
+6.24%
6M Leistung:
+56.14%
1J Leistung:
+6.81%
1-Tages-Spanne:
$9.02
$10.17
1-Wochen-Bereich:
$9.02
$10.39
52-Wochen-Spanne:
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.04 | 476.88M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
122.06 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.30 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.87 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.21 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.82 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Emergent Biosolutions marks 10 years since FDA approval of NARCAN with Emmitt Smith - Traders Union
Why Emergent BioSolutions Inc. stock could outperform in 2025Weekly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Why Emergent BioSolutions Inc. (ER4) stock remains top ratedChart Signals & Smart Money Movement Tracker - newser.com
Is Emergent BioSolutions Inc. stock undervalued at current price2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
Is Emergent BioSolutions Inc. stock undervalued historicallyJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is trending on social media2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Will Emergent BioSolutions Inc. stock deliver consistent dividends2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Can Emergent BioSolutions Inc. stock deliver consistent EPS growth2025 Volume Leaders & Verified Entry Point Signals - newser.com
Will Emergent BioSolutions Inc. stock gain from green policiesJuly 2025 Opening Moves & Scalable Portfolio Growth Ideas - newser.com
How Emergent BioSolutions Inc. stock compares with tech leadersPortfolio Update Summary & Entry Point Strategy Guides - newser.com
How dovish Fed policy supports Emergent BioSolutions Inc. stockJuly 2025 Market Mood & High Accuracy Trade Signal Alerts - newser.com
Why millennials buy Emergent BioSolutions Inc. (ER4) stockPrice Action & AI Driven Stock Movement Reports - newser.com
Is Emergent BioSolutions Inc. stock resilient in recession scenariosPortfolio Gains Report & Daily Technical Forecast Reports - newser.com
Visual analytics tools that track Emergent BioSolutions Inc. performanceWeekly Investment Recap & Daily Stock Momentum Reports - newser.com
What makes Emergent BioSolutions Inc. stock appealing to growth investorsEarnings Overview Report & AI Powered Trade Plan Recommendations - newser.com
Understanding Emergent BioSolutions Inc.’s price movement2025 Major Catalysts & Weekly Sector Rotation Insights - newser.com
Published on: 2025-11-19 05:25:17 - newser.com
Published on: 2025-11-19 04:54:10 - newser.com
Chart based exit strategy for Emergent BioSolutions Inc.2025 Biggest Moves & Community Consensus Picks - newser.com
Reversal indicators forming on Emergent BioSolutions Inc. stockDay Trade & Daily Technical Stock Forecast Reports - newser.com
What technical patterns form on Emergent BioSolutions Inc. (ER4) stock charts - newser.com
Editor: 【Capital Growth】 - newser.com
Emergent’s NARCAN nasal spray marks 10 years since FDA approval By Investing.com - Investing.com Nigeria
Emergent’s NARCAN nasal spray marks 10 years since FDA approval - Investing.com India
Emergent BioSolutions marks 10-year anniversary of the U.S. FDA approval of Narcan nasal spray and reinforces its commitment to increasing naloxone access - MarketScreener
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access - The Manila Times
Emergent BioSolutions (NYSE: EBS) marks 10 years of NARCAN, 85M doses used - Stock Titan
Analyzing Emergent BioSolutions Inc. with multi timeframe chartsJuly 2025 Big Picture & Growth Focused Stock Reports - newser.com
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):